Daridorexant

Quviviq 50 MG Comprimidos Recubiertos con Pelicula

54,04 mg comprimido recubierto con películaSpainMarketedAuthorised 28 Dec 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

QuviviqEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Daridorexant

Quviviq 50 MG Comprimidos Recubiertos con Pelicula

54,04 mg comprimido recubierto con películaSpainMarketedAuthorised 28 Dec 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

QuviviqEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Quviviq 50 mg, filmomhulde tabletNetherlands · Filmomhulde tablet · Idorsia Pharmaceuticals Deutschland GmbH

QuviviqUnited States · 25MG BASE, 50MG BASE · tablet · Idorsia

Packs

Pack	Code	Status
QUVIVIQ 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 10 comprimidos	760147
QUVIVIQ 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 30 comprimidos	760148

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Daridorexant
Strength: 54,04 mg
Dosage form: comprimido recubierto con película
Route: vía oral
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 28 Dec 2022
Registration: 1221638003
Marketing authorisation holder: Idorsia Pharmaceuticals Deutschland Gmbh
Procedure: EU centralised
Supply: Medicamento Sujeto A Prescripción Médica
EU number: EU/1/22/1638